Outlook Therapeutics, Inc.
OTLK
$2.41
-$0.2901-10.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 56.53% | -366.76% | 205.34% | -87.18% | 138.86% |
| Total Depreciation and Amortization | 1.03% | 1.04% | 0.00% | 0.35% | 1.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -83.08% | 201.15% | -30.98% | 56.70% | -164.59% |
| Change in Net Operating Assets | 136.90% | -185.97% | 63.21% | 337.25% | -41.07% |
| Cash from Operations | 28.24% | -51.21% | 35.42% | 12.97% | -1.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 97.24% | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -22.44% | 947.26% | -- | -- | -92.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -28.16% | 958.17% | 1,615.13% | -102.67% | -92.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.47% | 120.09% | 46.04% | -12.44% | -141.24% |